Key result
Diabetes was not associated with reduced in-vitro venous prostacyclin production compared to controls (medians 0.11 vs 0.19 ng/mg tissue), failing to support a link with diabetic retinopathy.
Why the study?
Does in-vitro venous prostacyclin production or plasma 6-keto-prostaglandin F1 alpha concentration correlate with the presence or severity of diabetic retinopathy?
Observational (n=46)
Does in-vitro venous prostacyclin production or plasma 6-keto-prostaglandin F1 alpha concentration correlate with the presence or severity of diabetic retinopathy?
Absolute Event Rate: 0.11% vs 0.19%
The findings do not support an association between reduced venous prostacyclin production and the development of diabetic retinopathy.
Challenges prostacyclin deficiency as a retinopathy driver; hypothesis-generating and requires prospective validation before mechanistic conclusions.
Previous studies have shown that vessels from diabetics produce less prostacyclin in vitro than those from normal controls. To determine whether this decreased production is related to complications elective biopsy of a superficial forearm vein was performed on 12 insulin-dependent male diabetics, six with nil or minimal and six with proliferative retinopathy, and seven male controls. Vein segments from the diabetics and controls produced similar amounts of prostacyclin in vitro (medians 0.11 and 0.19 ng/mg tissue respectively), but the segments from the diabetics with nil or minimal retinopathy produced less than those from the diabetics with proliferative retinopathy (medians 0.09 and 0.18 ng/mg respectively). Preoperative plasma immunoreactive concentrations of 6-keto-prostaglandin F1 alpha were not significantly different between the controls and the diabetics (medians 101 and 116 pg/ml respectively). In a separate study, however, 11 diabetics with duration of disease of over 10 years and nil or minimal retinopathy had significantly lower concentrations than a matched group of 16 with background or proliferative retinopathy (medians 79 and 121 pg/ml respectively). These results do not support an association between reduced prostacyclin production and diabetic retinopathy.
No takes yet. Share an insight, caveat, or question.
Davis et al. (1981) conducted an observational in Diabetic retinopathy (n=46). Diabetes mellitus and diabetic retinopathy vs. Healthy controls or diabetics with nil/minimal retinopathy was evaluated on In-vitro venous prostacyclin production (ng/mg tissue). Diabetes was not associated with reduced in-vitro venous prostacyclin production compared to controls (medians 0.11 vs 0.19 ng/mg tissue), failing to support a link with diabetic retinopathy.
Synapse has enriched one closely related paper. Consider it for comparative context: